[Role of angiotensin II receptor type 2 in predicting biochemical recurrence in the treatment of prostate cancer].

Autor:	Chibichyan MB; Institute of Arid Zones of Southern Scientific Center of RAS, Rostov-on-Don.; Rostov State Medical University, Rostov-on-Don., Kogan MI; Institute of Arid Zones of Southern Scientific Center of RAS, Rostov-on-Don.; Rostov State Medical University, Rostov-on-Don., Chernogubova EA; Institute of Arid Zones of Southern Scientific Center of RAS, Rostov-on-Don.; Rostov State Medical University, Rostov-on-Don., Pavlenko IA; Rostov Region Pathology and Autopsy Bureau, Rostov-on-Don., Matishov DG; Institute of Arid Zones of Southern Scientific Center of RAS, Rostov-on-Don.
Jazyk:	ruština
Zdroj:	Urologiia (Moscow, Russia : 1999) [Urologiia] 2016 Dec (6), pp. 89-94.
Abstrakt:	Aim: To identify markers for predicting aggressive forms of prostate cancer. Materials and Methods: The study retrospectively evaluated expression of angiotensin II type 2 receptors (AT2-R) in prostate needle biopsy tissue from patients with and without biochemical recurrence after combined hormone and radiation therapy. Results: The study findings showed that low expression of AT2-R in prostate tissue was associated with a high risk of biochemical recurrence. The data on the nature of AT2-R expression in prostate tissue of prostate cancer patients may be considered as a tool for predicting biochemical recurrence after combined hormone and radiation therapy. The test has a sensitivity of 87.5% and specificity of 85.71%.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu